Prostate cancer is diverse in clinical presentation, histopathological tumor growth patterns, and survival.
Therefore, individual assessment of a tumor's aggressive potential is crucial for clinical decision-making in men with prostate cancer. To date a large number of prognostic markers for prostate cancer have been described, most of them based on radical prostatectomy specimens. However, in order to affect clinical decision-making, validation of respective markers in pretreatment diagnostic needle-biopsies is essential. Here, we discuss established and promising histopathological and molecular parameters in diagnostic needle-biopsies.
Hoogland AM, Kweldam CF, van Leenders GJ. Are you the author?
Department of Pathology, Josephine Nefkens Institute, Room Be-206, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
Reference: Biomed Res Int. 2014;2014:341324.